Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich’s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10–13, 2026, in Atlanta, Georgia.